On May 14, 2026 Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, reported its financial results for the first quarter ended March 31, 2026 and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are encouraged by our continued quarter-over-quarter growth and strong start to the year. 2026 is a defining period for Fennec, with growing clinical interest in independently evaluating PEDMARK (sodium thiosulfate injection) across new patient populations and tumor types that reinforces our confidence in its broader potential," said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals. "At the same time, the strategic enhancements we’ve made to our field force are already sharpening our execution and expanding our reach – in tandem, the positive experiences we’re seeing through our Fennec HEARS program are translating into meaningful access and strong conversion rates, resulting in more patients being treated. Coupled with our solid financial foundation, we believe we are well-positioned to continue to build momentum and deliver sustained growth throughout 2026."

Business Highlights:

Continued Growth Within Key PEDMARK Accounts: Adoption continues to build across both new and existing accounts, with established prescribers demonstrating growing confidence in PEDMARK, contributing to deeper utilization and higher vials per account. Demand in the first quarter was driven by prescribing in three core tumor types: testicular, cervical and head and neck cancers, and these remain foundational to Fennec’s commercial opportunity. Additionally, our comprehensive patient services HUB, Fennec HEARS, continues to be an important contributor to PEDMARK utilization and HCP adoption. Through ongoing operational refinements, we are seeing more patients enter the funnel, while the overall experience for those patients continues to improve.

Initiation of Third Institution-Led Clinical Study: In April 2026, Fennec announced the initiation of an investigator-sponsored study by the University of Arizona Cancer Center to evaluate use of PEDMARK in AYA and adult patients with head and neck and testicular cancers receiving cisplatin. Additional investigator-initiated studies supporting the use of PEDMARK have been submitted to Fennec and are currently under review.

2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting: Four abstracts evaluating PEDMARK were accepted as part of the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting program, taking place May 29-June 2, 2026 in Chicago, IL.
Upcoming Events:

Annual Meeting of Shareholders: Fennec would like to invite shareholders to participate in the Company’s Annual General Meeting on Tuesday, Wednesday June 10, 2026 at 10:00 a.m. ET, which will be held virtually and online by visiting www.virtualshareholdermeeting.com/FENC2026.

Investor Conferences: Fennec will be participating in the following upcoming investor conferences:

H.C. Wainwright 4th Annual BioConnect Conference, held in partnership with Nasdaq in NYC, on May 19, 2026;
B. Riley Securities 2026 Annual Investor Conference in Los Angeles, CA, on May 20 & 21, 2026;
24th Annual Craig-Hallum Institutional Investor Conference being held in Minneapolis, MN on May 28, 2026.

(Press release, Fennec Pharmaceuticals, MAY 14, 2026, View Source [SID1234669322])